$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000147929016000031 Filed on March 04, 2016

Income Statement

Concept	2015 Q4	2015	2014 Q4
Revenue	$75.00K	$300.0K	$75.00K
YoY Change	0.0%	-21.67%	-75.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.910M	$25.09M	$4.790M
YoY Change	44.26%	31.74%	59.67%
% of Gross Profit
Research & Development	$14.96M	$47.53M	$9.130M
YoY Change	63.86%	42.35%	46.31%
% of Gross Profit
Depreciation & Amortization	$410.0K	$1.995M	$490.0K
YoY Change	-16.33%	-5.0%	0.0%
% of Gross Profit
Operating Expenses	$21.86M	$72.62M	$13.92M
YoY Change	57.04%	38.49%	50.65%
Operating Profit		-$72.32M
YoY Change		38.94%
Interest Expense	-$200.0K	$1.190M	-$200.0K
YoY Change	0.0%	-88.85%	25.0%
% of Operating Profit
Other Income/Expense, Net	-$110.0K	-$327.0K	-$160.0K
YoY Change	-31.25%	39.74%	-83.84%
Pretax Income	-$22.09M	-$73.48M	-$14.21M
YoY Change	55.45%	16.78%	40.97%
Income Tax
% Of Pretax Income
Net Earnings	-$22.09M	-$73.50M	-$14.21M
YoY Change	55.46%	16.85%	40.95%
Net Earnings / Revenue	-29458.67%	-24500.0%	-18949.33%
Basic Earnings Per Share	-$0.83	-$3.02	-$0.60
Diluted Earnings Per Share	-$0.83	-$3.02	-$0.60
COMMON SHARES
Basic Shares Outstanding	28.06M shares	24.34M shares	23.72M shares
Diluted Shares Outstanding		24.34M shares

Balance Sheet

Concept	2015 Q4	2015	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.3M	$252.3M	$171.0M
YoY Change	47.54%	47.54%	4284.62%
Cash & Equivalents	$201.6M	$201.6M	$171.0M
Short-Term Investments	$50.70M	$50.70M
Other Short-Term Assets	$267.0K	$1.500M	$239.0K
YoY Change	11.72%	7.14%	246.38%
Inventory
Prepaid Expenses	$1.200M		$1.085M
Receivables	$75.00K	$200.0K	$300.0K
Other Receivables	$83.00K	$0.00	$0.00
Total Short-Term Assets	$254.0M	$254.0M	$172.7M
YoY Change	47.03%	47.08%	3488.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.71M	$19.70M	$19.27M
YoY Change	2.25%	2.07%	34.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.800M	$1.800M
YoY Change
Other Assets	$0.00	$400.0K	$29.00K
YoY Change	-100.0%	-20.0%	-99.04%
Total Long-Term Assets	$21.86M	$21.80M	$19.74M
YoY Change	10.75%	10.1%	10.69%
TOTAL ASSETS
Total Short-Term Assets	$254.0M	$254.0M	$172.7M
Total Long-Term Assets	$21.86M	$21.80M	$19.74M
Total Assets	$275.8M	$275.8M	$192.5M
YoY Change	43.31%	43.27%	749.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.657M	$2.700M	$3.149M
YoY Change	-15.62%	-12.9%	-43.01%
Accrued Expenses	$6.245M	$5.500M	$4.145M
YoY Change	50.66%	48.65%	-0.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.100M	$3.100M	$2.900M
YoY Change	6.9%	6.9%	-87.34%
Total Short-Term Liabilities	$12.04M	$12.00M	$10.24M
YoY Change	17.59%	17.65%	-78.48%
LONG-TERM LIABILITIES
Long-Term Debt	$5.300M	$5.300M	$600.0K
YoY Change	783.33%	783.33%	-84.62%
Other Long-Term Liabilities	$0.00	$5.200M	$5.300M
YoY Change	-100.0%	-1.89%	10.42%
Total Long-Term Liabilities	$0.00	$10.50M	$5.900M
YoY Change	-100.0%	77.97%	-32.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.04M	$12.00M	$10.24M
Total Long-Term Liabilities	$0.00	$10.50M	$5.900M
Total Liabilities	$22.57M	$22.60M	$16.10M
YoY Change	40.19%	40.37%	-71.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.3M		-$258.8M
YoY Change	28.39%		32.12%
Common Stock	$585.6M		$435.2M
YoY Change	34.56%		1035.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$253.3M	$253.3M	$176.4M
YoY Change
Total Liabilities & Shareholders Equity	$275.8M	$275.8M	$192.5M
YoY Change	43.31%	43.27%	749.94%

Cashflow Statement

Concept	2015 Q4	2015	2014 Q4
OPERATING ACTIVITIES
Net Income	-$22.09M	-$73.50M	-$14.21M
YoY Change	55.46%	16.85%	40.95%
Depreciation, Depletion And Amortization	$410.0K	$1.995M	$490.0K
YoY Change	-16.33%	-5.0%	0.0%
Cash From Operating Activities	-$16.45M	-$55.67M	-$9.120M
YoY Change	80.37%	1.08%	-34.76%
INVESTING ACTIVITIES
Capital Expenditures	-$480.0K	$3.328M	-$1.540M
YoY Change	-68.83%	-52.29%	-59.58%
Acquisitions
YoY Change
Other Investing Activities	$920.0K	-$53.09M
YoY Change
Cash From Investing Activities	$440.0K	-$56.42M	-$1.610M
YoY Change	-127.33%	708.82%	-57.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$10.02M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	127.1M	$142.6M	-5.800M
YoY Change	-2290.52%	-37.76%	-129.31%
NET CHANGE
Cash From Operating Activities	-16.45M	-$55.67M	-9.120M
Cash From Investing Activities	440.0K	-$56.42M	-1.610M
Cash From Financing Activities	127.1M	$142.6M	-5.800M
Net Change In Cash	111.0M	$30.51M	-16.53M
YoY Change	-771.75%	-81.74%	-922.39%
FREE CASH FLOW
Cash From Operating Activities	-$16.45M	-$55.67M	-$9.120M
Capital Expenditures	-$480.0K	$3.328M	-$1.540M
Free Cash Flow	-$15.97M	-$59.00M	-$7.580M
YoY Change	110.69%	-4.92%	-25.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2014Q4	rvnc	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	322000	USD
CY2015Q4	rvnc	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	1300000	USD
CY2014Q4	rvnc	Accrued Construction In Progress Expenditures Not Yet Paid Current AccruedConstructionInProgressExpendituresNotYetPaidCurrent	60000	USD
CY2015Q4	rvnc	Accrued Construction In Progress Expenditures Not Yet Paid Current AccruedConstructionInProgressExpendituresNotYetPaidCurrent	25000	USD
CY2014Q4	rvnc	Accrued Manufacturing Costs AccruedManufacturingCosts	361000	USD
CY2015Q4	rvnc	Accrued Manufacturing Costs AccruedManufacturingCosts	207000	USD
CY2014Q4	rvnc	Accrued Milestone Obligations AccruedMilestoneObligations	577000	USD
CY2015Q4	rvnc	Accrued Milestone Obligations AccruedMilestoneObligations	471000	USD
CY2014	rvnc	Adjustmentsto Additional Paidin Capital Terminationof Repurchase Rights Relatedto Vestingof Common Stock Issued Pursuantto Early Exercises AdjustmentstoAdditionalPaidinCapitalTerminationofRepurchaseRightsRelatedtoVestingofCommonStockIssuedPursuanttoEarlyExercises	58000	USD
CY2015Q4	rvnc	Annual Releaseof Restricted Cash AnnualReleaseofRestrictedCash	75000	USD
CY2014Q4	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	0	USD
CY2015Q4	rvnc	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	1751000	USD
CY2015Q4	rvnc	Cash Cash Equivalentsand Investments CashCashEquivalentsandInvestments	254054000	USD
CY2015	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
CY2013	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-743000	USD
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28433208	shares
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2015	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
CY2015	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
CY2015Q2	dei	Entity Public Float EntityPublicFloat	469500000	USD
CY2015	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2014Q4	rvnc	Accrued Capital Expenditures AccruedCapitalExpenditures	266000	USD
CY2015Q4	rvnc	Accrued Capital Expenditures AccruedCapitalExpenditures	262000	USD
CY2014	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	-210000	USD
CY2015	rvnc	Changein Fair Valueof Convertible Preferred Stock Warrant ChangeinFairValueofConvertiblePreferredStockWarrant	0	USD
CY2015	rvnc	Common Stock Voting Rights Numberof Votesper Share CommonStockVotingRightsNumberofVotesperShare	1	votes_per_share
CY2013	rvnc	Conversion Of Convertible Preferred Stock Warrant ConversionOfConvertiblePreferredStockWarrant	1168000	USD
CY2014	rvnc	Conversion Of Convertible Preferred Stock Warrant ConversionOfConvertiblePreferredStockWarrant	0	USD
CY2015	rvnc	Conversion Of Convertible Preferred Stock Warrant ConversionOfConvertiblePreferredStockWarrant	0	USD
CY2013	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
CY2014	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	1441000	USD
CY2015	rvnc	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	0	USD
CY2013	rvnc	Deemed Dividend Associated With Beneficial Conversion Of Convertible Preferred Stock DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock	177000	USD
CY2014	rvnc	Deemed Dividend Associated With Beneficial Conversion Of Convertible Preferred Stock DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock	0	USD
CY2015	rvnc	Deemed Dividend Associated With Beneficial Conversion Of Convertible Preferred Stock DeemedDividendAssociatedWithBeneficialConversionOfConvertiblePreferredStock	0	USD
CY2014Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	5223000	USD
CY2015Q4	rvnc	Deferred Tax Assets Fixedandintangibleassets DeferredTaxAssetsFixedandintangibleassets	4935000	USD
CY2015Q4	rvnc	Deferred Tax Assets Tax Deferred Expense Compensationand Benefits Sharebased Compensation Cost Excludedfrom Net Operating Loss DeferredTaxAssetsTaxDeferredExpenseCompensationandBenefitsSharebasedCompensationCostExcludedfromNetOperatingLoss	8000000	USD
CY2015	rvnc	Defined Benefit Plan Ageat Which Benefits Are Provided DefinedBenefitPlanAgeatWhichBenefitsAreProvided	P18Y
CY2013	rvnc	Effective Income Tax Reconciliation Permanent Differences EffectiveIncomeTaxReconciliationPermanentDifferences	3931000	USD
CY2014	rvnc	Effective Income Tax Reconciliation Permanent Differences EffectiveIncomeTaxReconciliationPermanentDifferences	660000	USD
CY2015	rvnc	Effective Income Tax Reconciliation Permanent Differences EffectiveIncomeTaxReconciliationPermanentDifferences	224000	USD
CY2013	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2014	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	1356000	USD
CY2015Q4	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	9102000	USD
CY2015Q4	rvnc	Financing Obligation Future Minimum Payments Duein Three Years FinancingObligationFutureMinimumPaymentsDueinThreeYears	949000	USD
CY2015Q4	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	3936000	USD
CY2015Q4	rvnc	Financing Obligation Future Minimum Payments Next Twelve Months FinancingObligationFutureMinimumPaymentsNextTwelveMonths	4217000	USD
CY2013	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2014	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	-1356000	USD
CY2015	rvnc	Gain Loss On Settlement In Exchange Of Preferred Stock Warrants GainLossOnSettlementInExchangeOfPreferredStockWarrants	0	USD
CY2013	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	47000	USD
CY2014	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-320000	USD
CY2015	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	127000	USD
CY2013	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	453000	USD
CY2015	rvnc	Extinguishmentof Warrant Liability Upon Exerciseof Put Option ExtinguishmentofWarrantLiabilityUponExerciseofPutOption	0	USD
CY2013	rvnc	Fair Valueof Warrants Issued FairValueofWarrantsIssued	0	USD
CY2014	rvnc	Fair Valueof Warrants Issued FairValueofWarrantsIssued	379000	USD
CY2015	rvnc	Fair Valueof Warrants Issued FairValueofWarrantsIssued	0	USD
CY2014Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	598000	USD
CY2015Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	5346000	USD
CY2014Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	307000	USD
CY2015Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	3135000	USD
CY2013	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	500000	USD
CY2014	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	972000	USD
CY2015	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2013	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	9409000	USD
CY2014	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	1250000	USD
CY2015	rvnc	Interest Expense Convertible Notes InterestExpenseConvertibleNotes	0	USD
CY2013	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	490000	USD
CY2014	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	203000	USD
CY2015	rvnc	Interest Expense Debt Issuance Costs InterestExpenseDebtIssuanceCosts	39000	USD
CY2013	rvnc	Interest Expense On Notes Payable InterestExpenseOnNotesPayable	9220000	USD
CY2014	rvnc	Interest Expense On Notes Payable InterestExpenseOnNotesPayable	0	USD
CY2015	rvnc	Interest Expense On Notes Payable InterestExpenseOnNotesPayable	0	USD
CY2013	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	4128000	USD
CY2014	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	650000	USD
CY2015	rvnc	Interest Expense Warrantand Derivative Related Debt Discounts InterestExpenseWarrantandDerivativeRelatedDebtDiscounts	5000	USD
CY2013	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
CY2014	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	6490000	USD
CY2015	rvnc	Issuance Of Common Stock Upon Net Exercise Of Warrants IssuanceOfCommonStockUponNetExerciseOfWarrants	0	USD
CY2013	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	2737000	USD
CY2014	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	981000	USD
CY2015	rvnc	Issuance Of Common Stock Warrants IssuanceOfCommonStockWarrants	0	USD
CY2013	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	139000	USD
CY2014	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	80000	USD
CY2015	rvnc	Issuance Of Convertible Preferred Stock Warrants IssuanceOfConvertiblePreferredStockWarrants	0	USD
CY2013	rvnc	Issuanceof Common Stock Warrants Convertible Preferred Stock Financing IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing	4272000	USD
CY2014	rvnc	Issuanceof Common Stock Warrants Convertible Preferred Stock Financing IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing	0	USD
CY2015	rvnc	Issuanceof Common Stock Warrants Convertible Preferred Stock Financing IssuanceofCommonStockWarrantsConvertiblePreferredStockFinancing	0	USD
CY2013	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	0	USD
CY2014	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	546000	USD
CY2015	rvnc	Non Cash Deferred Followon Public Offering Costs NonCashDeferredFollowonPublicOfferingCosts	0	USD
CY2013	rvnc	Non Cumulative Dividend Preferred Stock NonCumulativeDividendPreferredStock	13878000	USD
CY2014	rvnc	Non Cumulative Dividend Preferred Stock NonCumulativeDividendPreferredStock	0	USD
CY2015	rvnc	Non Cumulative Dividend Preferred Stock NonCumulativeDividendPreferredStock	0	USD
CY2013	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	2490000	USD
CY2014	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	4028000	USD
CY2015	rvnc	Noncash Deferred Initial Public Offering Costs NoncashDeferredInitialPublicOfferingCosts	0	USD
CY2013	rvnc	Noncash Interest Expense NoncashInterestExpense	13574000	USD
CY2014	rvnc	Noncash Interest Expense NoncashInterestExpense	9490000	USD
CY2015	rvnc	Noncash Interest Expense NoncashInterestExpense	388000	USD
CY2014	rvnc	Proceeds From Issuanceof Follow On Offering ProceedsFromIssuanceofFollowOnOffering	131880000	USD
CY2015	rvnc	Proceeds From Issuanceof Follow On Offering ProceedsFromIssuanceofFollowOnOffering	126230000	USD
CY2015Q4	rvnc	Restricted Cash Minimum Balance RestrictedCashMinimumBalance	400000	USD
CY2013	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	-425000	USD
CY2014	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	210000	USD
CY2015	rvnc	Revaluation Of Convertible Redeemable Preferred Stock Warrants RevaluationOfConvertibleRedeemablePreferredStockWarrants	0	USD
CY2014Q1	rvnc	Stock Issued During Period Shares Conversionof Convertible Securities Equity StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesEquity	8689999	shares
CY2014	rvnc	Stock Issued During Period Value Conversionof Convertible Securities Debt StockIssuedDuringPeriodValueConversionofConvertibleSecuritiesDebt	26206000	USD
CY2014	rvnc	Stock Issued During Period Value Conversionof Convertible Securities Equity StockIssuedDuringPeriodValueConversionofConvertibleSecuritiesEquity	123981000	USD
CY2013	rvnc	Stock Issued During Period Value New Issues Exerciseof Common Stock Warrants StockIssuedDuringPeriodValueNewIssuesExerciseofCommonStockWarrants	7000	USD
CY2014	rvnc	Stock Issued During Period Value New Issues Follow On Offering StockIssuedDuringPeriodValueNewIssuesFollowOnOffering	131335000	USD
CY2015	rvnc	Stock Issued During Period Value New Issues Follow On Offering StockIssuedDuringPeriodValueNewIssuesFollowOnOffering	126230000	USD
CY2014	rvnc	Stock Issued During Period Value New Issues Upon Net Exerciseof Common Stock Warrantsand Related Extinguishmentof Warranty Liabilityin Connectionwith Initial Public Offering StockIssuedDuringPeriodValueNewIssuesUponNetExerciseofCommonStockWarrantsandRelatedExtinguishmentofWarrantyLiabilityinConnectionwithInitialPublicOffering	6490000	USD
CY2014	rvnc	Temporary Equity Stock Issued During Period Shares New Issues Initial Public Offering TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesInitialPublicOffering	-8689999	shares
CY2014	rvnc	Temporary Equity Stock Issued During Period Value New Issues Initial Public Offering TemporaryEquityStockIssuedDuringPeriodValueNewIssuesInitialPublicOffering	-123982000	USD
CY2014Q1	rvnc	Tenant Improvement Allowance TenantImprovementAllowance	3000000.0	USD
CY2013	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2014	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	58000	USD
CY2015	rvnc	Terminationof Stock Option Repurchase Right Noncash TerminationofStockOptionRepurchaseRightNoncash	0	USD
CY2015Q4	rvnc	Working Capital Surplus WorkingCapitalSurplus	241900000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3149000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2657000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	300000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	158000	USD
CY2013	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-601000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4145000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6245000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9906000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11472000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-40000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	435142000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	585537000	USD
CY2015	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	993000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	548000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6513000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12388000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	379000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	548000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6530000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12388000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	4128000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1250000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	217000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	203000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	39000	USD
CY2014Q4	us-gaap	Assets Assets	192469000	USD
CY2015Q4	us-gaap	Assets Assets	275822000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	172731000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	253963000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	166038000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	198186000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	40000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	166038000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	198226000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	50688000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52439000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4083000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3914000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171032000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201615000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-169000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	167118000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30583000	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.15
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	606457	shares
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1182092	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23774465	shares
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73516000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62917000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52448000	USD
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28288464	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23774465	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28288464	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2014	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	500000	USD
CY2015	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	30000	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	123982000	USD
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2013	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	74894000	USD
CY2014	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2015	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2014Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1	shares
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1095000	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	26206000	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3725000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3773000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	92859000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	115949000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2623000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3311000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1602000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3367000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2458000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2371000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	104765000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	129933000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	0	USD
CY2013	us-gaap	Depreciation Depreciation	1900000	USD
CY2013	us-gaap	Depreciation Depreciation	1881000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2014	us-gaap	Depreciation Depreciation	2051000	USD
CY2014	us-gaap	Depreciation Depreciation	2100000	USD
CY2015	us-gaap	Depreciation Depreciation	2000000	USD
CY2015	us-gaap	Depreciation Depreciation	1995000	USD
CY2014Q1	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Liability At Fair Value DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue	7100000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1541000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1414000	USD
CY2013	us-gaap	Dilutive Securities DilutiveSecurities	825000	USD
CY2014	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2015	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.17
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.24
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.02
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.05
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.24
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.02
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2088000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3282000	USD
CY2013	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	32008000	USD
CY2014	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
CY2015	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	USD
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	621000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2151000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013	us-gaap	Financing Interest Expense FinancingInterestExpense	0	USD
CY2014	us-gaap	Financing Interest Expense FinancingInterestExpense	28000	USD
CY2015	us-gaap	Financing Interest Expense FinancingInterestExpense	344000	USD
CY2013	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	2660000	USD
CY2014	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	4032000	USD
CY2015	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-38000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	24667000	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-8331000	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2013	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2014	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	3000	USD
CY2015	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10522000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16226000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17832000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-21392000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24982000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	2888000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	756000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Amortization IncomeTaxReconciliationNondeductibleExpenseAmortization	0	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	284000	USD
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	537000	USD
CY2015	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	607000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	849000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	79000	USD
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	0	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	642000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-3137000	USD
CY2015	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	516000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3193000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3399000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-692000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3832000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2311000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3179000	USD
CY2013	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-6927000	USD
CY2014	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-7073000	USD
CY2015	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2770000	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1621000	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-29000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-422000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	999000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	192000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-133000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-549000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-200000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2013	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1590000	USD
CY2014	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1182000	USD
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-75000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	641275	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	167655	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2013	us-gaap	Interest Expense InterestExpense	15164000	USD
CY2014	us-gaap	Interest Expense InterestExpense	10672000	USD
CY2015	us-gaap	Interest Expense InterestExpense	1190000	USD
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	273000	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	271000	USD
CY2015	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	802000	USD
CY2013	us-gaap	Interest Paid InterestPaid	1590000	USD
CY2014	us-gaap	Interest Paid InterestPaid	1182000	USD
CY2015	us-gaap	Interest Paid InterestPaid	802000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	23000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2013	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000	USD
CY2014	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	44000	USD
CY2015	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	231000	USD
CY2013	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	379000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P15Y
CY2014Q4	us-gaap	Liabilities Liabilities	16100000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	22570000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192469000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	275822000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10236000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12037000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	1751000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53991000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	229091000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	142592000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6402000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6900000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56340000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47758000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55073000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55669000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-52448000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-52400000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-21426000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-13302000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-13977000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-14212000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-62917000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-62900000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-15402000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-16805000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-19175000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-22094000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-73500000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-73476000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	258000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21426000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13302000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13977000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14212000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62917000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15402000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16805000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19175000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22094000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73476000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1083000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21426000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13302000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13977000	USD
CY2014Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14212000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-62917000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-15402000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16805000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19175000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22094000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-73476000	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	2285000	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	1348000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	487000	USD
CY2013	us-gaap	Notes Assumed1 NotesAssumed1	5750000	USD
CY2014	us-gaap	Notes Assumed1 NotesAssumed1	1050000	USD
CY2015	us-gaap	Notes Assumed1 NotesAssumed1	0	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2635000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5394000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	38842000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	52433000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	72617000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-38225000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-52050000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-72317000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	48548000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	72800000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	5222000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5763000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5578000	USD
CY2015Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26591000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4400000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5200000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5300000	USD
CY2015	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	239000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	267000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-40000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	448000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	698000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-404000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-234000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-327000	USD
CY2013	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	1438000	USD
CY2015	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2013	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	132000	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9000000	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	993000	USD
CY2013	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2014	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2015	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	54087000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6477000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6975000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3328000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1624000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1625000	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2013	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	1000000	USD
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	21903000	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	6750000	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1085000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1200000	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	102672000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10021000	USD
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	40646000	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	29180000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1771000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2753000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	510000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	435000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	35000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31180000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19274000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19708000	USD
CY2015Q4	us-gaap	Purchase Obligation PurchaseObligation	20200000	USD
CY2013	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	982000	USD
CY2014	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	228000	USD
CY2015	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	2598000	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7594000	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12316000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2652000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27831000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33390000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47529000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	435000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-258797000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-332300000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-332273000	USD
CY2013	us-gaap	Revenues Revenues	617000	USD
CY2014Q1	us-gaap	Revenues Revenues	158000	USD
CY2014Q2	us-gaap	Revenues Revenues	75000	USD
CY2014Q3	us-gaap	Revenues Revenues	75000	USD
CY2014Q4	us-gaap	Revenues Revenues	75000	USD
CY2014	us-gaap	Revenues Revenues	383000	USD
CY2015Q1	us-gaap	Revenues Revenues	75000	USD
CY2015Q2	us-gaap	Revenues Revenues	75000	USD
CY2015Q3	us-gaap	Revenues Revenues	75000	USD
CY2015Q4	us-gaap	Revenues Revenues	75000	USD
CY2015	us-gaap	Revenues Revenues	300000	USD
CY2013	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	0	USD
CY2014	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	0	USD
CY2015	us-gaap	Sale Leaseback Transaction Net Proceeds Financing Activities SaleLeasebackTransactionNetProceedsFinancingActivities	9831000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11011000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19043000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25088000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	548000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	6530000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	12388000	USD
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.55
CY2013Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	22.50
CY2014Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	15.45
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	50688000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	349000	USD
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	318000	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	17000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10021000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	95433000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1422000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2435000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-216727000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-157549000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	176369000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	253252000	USD
CY2014Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	123982000	USD
CY2014Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	0	USD
CY2013	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	177000	USD
CY2014	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2015	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2014Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2015Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2015Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2012Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1517381	shares
CY2013Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	8689999	shares
CY2014Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2015Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2013	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	11256000	USD
CY2013	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	8133000	USD
CY2014	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2015	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2012000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2288000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1268000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1537000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1216000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	276000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	196000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	259000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	10000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19300000	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	25200000	USD
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1029150	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19391523	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24340466	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	220220	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19391523	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24340466	shares
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of short and long-term investments. Under the Company's Investment Policy, the Company limits its credit exposure by investing in highly liquid funds and debt obligations of the U.S. government and its agencies with high credit quality. The Company’s cash, cash equivalents, and investments are held in the United States of America. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash, cash equivalents, and investments.</font></div></div>
CY2015	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company and Medicis Pharmaceutical Corporation, or Medicis, entered into a license agreement granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational, injectable botulinum toxin type A product candidate. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 topical and RT002 injectable from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and the remaining </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2014, and (iii) </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT001 topical or RT002 injectable by the Company, or Product Approval Payment. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the Proceeds Sharing Arrangement Payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2013, the Proceeds Sharing Arrangement Payment derivative was remeasured to fair value. The fair value of the Proceeds Sharing Arrangement Payment derivative as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2013</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$6.7 million</font><font style="font-family:inherit;font-size:10pt;"> was determined using an option pricing model with the following assumption: expected term of </font><font style="font-family:inherit;font-size:10pt;">0.1</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">0.5</font><font style="font-family:inherit;font-size:10pt;"> years, risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">0.01%</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">0.10%</font><font style="font-family:inherit;font-size:10pt;"> and volatility of </font><font style="font-family:inherit;font-size:10pt;">37.00%</font><font style="font-family:inherit;font-size:10pt;"> - </font><font style="font-family:inherit;font-size:10pt;">47.50%</font><font style="font-family:inherit;font-size:10pt;">. Upon the completion of our IPO, we paid </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in settlement of our remaining obligation for the Proceeds Sharing Arrangement Payment. At the settlement date, the derivative liability was remeasured to the fair value of the obligation due, or </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">, and the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> to remeasure the fair value of the derivative for the remaining obligation through the date of settlement, or February 13, 2014. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the Product Approval Payment derivative as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> was determined by updating the estimate of the timing and probability of the related approval and a discount factor assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.5</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.2%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">3.5</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.4%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">9.0%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in mid-2019. The Company did not make any payments under the Product Approval Payment during the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the fair value measurements during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized an aggregate gain of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, an aggregate loss </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, and an aggregate gain of </font><font style="font-family:inherit;font-size:10pt;">$0.05 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock prior to the IPO, accruals, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives liability, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-16-000031-index-headers.html	Edgar Link	pending
0001479290-16-000031-index.html	Edgar Link	pending
0001479290-16-000031.txt	Edgar Link	pending
0001479290-16-000031-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph02.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20151231.xml	Edgar Link	completed
rvnc-20151231.xsd	Edgar Link	pending
rvnc-20151231_cal.xml	Edgar Link	unprocessable
rvnc-20151231_def.xml	Edgar Link	unprocessable
rvnc-20151231_lab.xml	Edgar Link	unprocessable
rvnc-20151231_pre.xml	Edgar Link	unprocessable
rvnc1231201510k.htm	Edgar Link	pending
rvnc1231201510kex1027.htm	Edgar Link	pending
rvnc1231201510kex1028.htm	Edgar Link	pending
rvnc1231201510kex1031.htm	Edgar Link	pending
rvnc1231201510kex1034.htm	Edgar Link	pending
rvnc1231201510kex106.htm	Edgar Link	pending
rvnc1231201510kex108.htm	Edgar Link	pending
rvnc1231201510kex211.htm	Edgar Link	pending
rvnc1231201510kex231.htm	Edgar Link	pending
rvnc1231201510kex311.htm	Edgar Link	pending
rvnc1231201510kex312.htm	Edgar Link	pending
rvnc1231201510kex321.htm	Edgar Link	pending
rvnc1231201510kex322.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2015 Q4 Form 10-K Financial Statement

#000147929016000031 Filed on March 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2015 Q4 Form 10-K Financial Statement

#000147929016000031 Filed on March 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc